| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement | PLoS Medicine | 2009 | 52,826 |
| 2 | Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement | Systematic Reviews | 2015 | 17,661 |
| 3 | The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration | PLoS Medicine | 2009 | 14,265 |
| 4 | Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement | Journal of Clinical Epidemiology | 2009 | 9,992 |
| 5 | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Journal of Clinical Epidemiology | 2009 | 8,797 |
| 6 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 7,596 |
| 7 | CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials | BMC Medicine | 2010 | 5,246 |
| 8 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria | Lancet Neurology, The | 2018 | 5,129 |
| 9 | The PRISMA 2020 statement: An updated guideline for reporting systematic reviews | International Journal of Surgery | 2021 | 4,731 |
| 10 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | Systematic Reviews | 2021 | 4,451 |
| 11 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 | JAMA Oncology | 2017 | 4,441 |
| 12 | Antithrombotic Therapy for VTE Disease | Chest | 2016 | 4,169 |
| 13 | From best evidence to best practice: effective implementation of change in patients' care | Lancet, The | 2003 | 3,690 |
| 14 | Lost in knowledge translation: Time for a map? | Journal of Continuing Education in the Health Professions | 2006 | 3,218 |
| 15 | The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement | PLoS Medicine | 2015 | 3,168 |
| 16 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 3,166 |
| 17 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,158 |
| 18 | Decision aids for people facing health treatment or screening decisions | The Cochrane Library | 2017 | 2,950 |
| 19 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up | Journal of the American College of Cardiology | 2020 | 2,484 |
| 20 | Audit and feedback: effects on professional practice and healthcare outcomes | The Cochrane Library | 2012 | 2,260 |
| 21 | Cellular and Molecular Regulation of Muscle Regeneration | Physiological Reviews | 2004 | 2,230 |
| 22 | PRDM16 controls a brown fat/skeletal muscle switch | Nature | 2008 | 2,044 |
| 23 | What is an adequate sample size? Operationalising data saturation for theory-based interview studies | Psychology and Health | 2010 | 1,990 |
| 24 | Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies | JAMA - Journal of the American Medical Association | 2018 | 1,962 |
| 25 | A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems | Implementation Science | 2017 | 1,928 |
| 26 | Scoping reviews: time for clarity in definition, methods, and reporting | Journal of Clinical Epidemiology | 2014 | 1,894 |
| 27 | Reprint—Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement | Physical Therapy | 2009 | 1,855 |
| 28 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 | JAMA Oncology | 2019 | 1,824 |
| 29 | Cetuximab for the Treatment of Colorectal Cancer | New England Journal of Medicine | 2007 | 1,800 |
| 30 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma | JAMA - Journal of the American Medical Association | 2017 | 1,778 |
| 31 | A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative Data | Medical Care | 2009 | 1,700 |
| 32 | Satellite Cells and the Muscle Stem Cell Niche | Physiological Reviews | 2013 | 1,699 |
| 33 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force | Value in Health | 2013 | 1,696 |
| 34 | CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials | International Journal of Surgery | 2012 | 1,653 |
| 35 | Knowledge translation of research findings | Implementation Science | 2012 | 1,653 |
| 36 | Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors | Clinics in Colon and Rectal Surgery | 2009 | 1,642 |
| 37 | The PRISMA 2020 statement: An updated guideline for reporting systematic reviews | PLoS Medicine | 2021 | 1,623 |
| 38 | Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015 | JAMA - Journal of the American Medical Association | 2017 | 1,591 |
| 39 | CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials | Journal of Clinical Epidemiology | 2010 | 1,555 |
| 40 | Effects of Exercise on Glycemic Control and Body Mass in Type 2 Diabetes Mellitus | JAMA - Journal of the American Medical Association | 2001 | 1,496 |
| 41 | AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews | Journal of Clinical Epidemiology | 2009 | 1,459 |
| 42 | Developing a quality criteria framework for patient decision aids: online international Delphi consensus process | BMJ: British Medical Journal | 2006 | 1,410 |
| 43 | A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth | Cancer Cell | 2007 | 1,392 |
| 44 | Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis | Nature Cell Biology | 2010 | 1,362 |
| 45 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,339 |
| 46 | Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray | Epigenetics | 2013 | 1,319 |
| 47 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 | JAMA Oncology | 2018 | 1,312 |
| 48 | Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism | New England Journal of Medicine | 2018 | 1,302 |
| 49 | Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement | Journal of Clinical Epidemiology | 2021 | 1,244 |
| 50 | Increasing value and reducing waste in research design, conduct, and analysis | Lancet, The | 2014 | 1,234 |
